Oliver Wolf’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (2)


Figure 1: Share of biopharmaceuticals in all pharmaceuticals launched between 1996 and 2005 Source: ETEPS 35 , IPTS calculations
Figure 2: Number of biopharmaceuticals available on the market Source: ETEPS 35 , IPTS calculations
Figure 3: Number of recombinant vaccines available on the market Source: ETEPS 37
Figure 5: Turnover of modern biotechnology products in the EU (2005) Source: ETEPS 62 , revenues of diagnostics calculated by IPTS
Figure 7: Average turnover per biopharmaceutical on the market (EUR million) Source: ETEPS 67 , IPTS calculations

+51

Consequences, opportunities and challenges of modern biotechnology for Europe, the Analysis Report: Contributions of modern biotechnology to European policy objectives
  • Technical Report
  • Full-text available

January 2008

·

300 Reads

·

1 Citation

·

Eleni Zika

·

Oliver Wolf

·

[...]

·

Consequences, opportunities and challenges of modern biotechnology for Europe The analysis report : contributions of modern biotechnology to European policy objectives Biotechnology is generally considered one of the key technologies of the 21st century, with a potentially wide range of applications in e.g. healthcare, agriculture, and industrial production processes. However, this notion has not yet been substantiated, as the diversity of sectors in which biotechnology is applied makes it difficult to investigate its actual degree of diffusion. Against this background and following a request from the European Parliament, the European Commission initiated the Biotechnology for Europe Study (Bio4EU Study). The study's objectives are to assess the contributions of modern biotechnology to the achievement of major European policy goals, and to increase public awareness and understanding of modern biotechnology. This report presents an analysis of the collected data with a view to assessing the contributions of modern biotechnology to major EU policy goals such as economic growth and job creation (Lisbon Agenda), and environmental sustainability and public health (Sustainable Development Strategy). As such, the study can be considered a background document of the Bio4EU synthesis report, which sets out the main findings of the study. • Add to favourites • Recommend this publication • Print publication details Corporate author(s): European Commission, Joint Research Centre Private author(s): Ilias Papatryfon, Eleni Zika, Oliver Wolf Themes: Medical and biological research Target audience: Scientific Key words: biotechnology, information analysis, report, economic growth, labour market, sustainable development, Community policy

Download

Citations (2)


... Beyond the number of products and applications existing on the market, or on the horizon, data on synthetic biology research in the private sector is extremely difficult to come by [63,[72][73][74]. There are a number of reasons for this, including the absence of triggers that feature in other sectors such as sales, patents, public companies, and government regulation. ...

Reference:

Locating Responsible Research and Innovation Within Access and Benefit Sharing Spaces of the Convention on Biological Diversity: the Challenge of Emerging Technologies
Consequences, Opportunities and Challenges of Modern Biotechnology for Europe

... The strategy of using a select set of markers persisted into the late-2000s. One estimate of the impact of MAS in the European Union was that in the livestock industry as a whole, MAS had been used in the breeding of between 40 and 80% of breeding females, and that the total direct economic contribution to the livestock industry had been 207-560 million euros (Papatryfon et al. 2008). 18 In the annual reports of Genus plc, the leading animal breeding company into which PIC became incorporated, the last mention of a strategy based on the identification of particular markers from the total set of genetic markers they had identified, was in 2009. ...

Consequences, opportunities and challenges of modern biotechnology for Europe, the Analysis Report: Contributions of modern biotechnology to European policy objectives